Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the transaction, the senior vice president now directly owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Laurie Keating also recently made the following trade(s):
- On Friday, December 1st, Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $135.89, for a total value of $4,076,700.00.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $129.07 on Friday. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals, Inc. has a 1 year low of $35.98 and a 1 year high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same period last year, the firm earned ($1.21) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.28 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the company. Fayerweather Charles purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $230,000. Watch Point Trust Co purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Segall Bryant & Hamill LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Security National Bank of SO Dak purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $247,000. Finally, Boston Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $247,000. Institutional investors and hedge funds own 88.39% of the company’s stock.
A number of research firms have weighed in on ALNY. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. B. Riley reiterated a “buy” rating and set a $205.00 target price (down previously from $220.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. Jefferies Group increased their target price on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, September 26th. Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $62.00 to $163.00 in a research report on Monday, October 2nd. Finally, Ladenburg Thalmann Financial Services restated a “buy” rating and set a $146.00 price target (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $121.20.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/alnylam-pharmaceuticals-inc-alny-svp-laurie-keating-sells-6249-shares-2.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.